Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion

Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently in exploratory Phase 1Upfront payment of US$1.15 billion and milestones up to US$450 millionView original content:https://www.prnewswire.co.uk/news-releases/vicebio-next-generation-vaccine-biotech-to-be-acquired-by-sanofi-for-us1-6-billion-302510462.html

en | boerse | 67997255 |